GleamWall
中文EN

ENTX Entera Bio Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%

Returns

ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$42,000$181,000
Cost of revenue$42,000$172,000
Gross profit$0$9,000
R&D expense$6.00M$4.50M
SG&A expense$398,000$340,000
Operating income-$11.53M-$9.59M
Pretax income-$11.44M-$9.53M
Income tax$0$14,000
Net income-$11.44M-$9.54M
EBITDA-$11.50M-$9.54M
EPS (basic)0.250.25
EPS (diluted)0.250.25
Weighted avg. shares (diluted)46.19M37.65M
Balance sheet
Cash & equivalents$7.11M$8.74M
Receivables$0$126,000
Current assets$15.30M$8.97M
PP&E, net$134,000$57,000
Total assets$15.99M$9.39M
Current liabilities$2.20M$1.18M
Total liabilities$2.89M$1.31M
Shareholders' equity$13.10M$8.08M
Shares outstanding46.18M38.84M
Cash flow statement
Operating cash flow-$7.37M-$6.82M
Capital expenditure$107,000$3,000
Free cash flow-$7.48M-$6.82M
Investing cash flow-$107,000-$3,000
Financing cash flow$13.71M$4.48M
Depreciation & amortization$30,000$46,000
Stock-based compensation$2.75M$2.56M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.